Aktienanalyse zu Krystal Biotech Inc (KRYS)KRYSKrystal Biotech Inc

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Krystal Biotech Inc is currently trading at $311.50, which is below several analyst price targets, including $400 from BofA and $441 from Goldman Sachs. However, the stock has a low RSI of 30.094, indicating potential overselling, and a forward P/E ratio of 46.95, suggesting it may be overvalued at this price. The recent performance shows a 1.60% decline over the last five days and a 9.92% drop over the last 20 days, indicating a bearish trend. The main risk is the forward P/E ratio of 46.95, which suggests that the stock may not be able to justify its current price based on future earnings expectations. Therefore, while there is potential for recovery, it may be prudent to hold rather than buy at this moment.

1 analysts cover KRYS: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 229.25.